Page last updated: 2024-12-08

echitamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

echitamine: RN given refers to parent cpd (3beta,16R)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	431721
MeSH ID	M0041230

Synonyms (4)

Synonym
6871-44-9
echitamine
methyl (1s,9r,10s,12s,13e,18s)-13-ethylidene-10-hydroxy-18-(hydroxymethyl)-15-methyl-8-aza-15-azoniapentacyclo[10.5.1.0^{1,9.0^{2,7.0^{9,15]octadeca-2,4,6-triene-18-carboxylate
B0005-148527

Research Excerpts

Dosage Studied

Excerpt	Relevance	Reference
" When given sub-cutaneously at a dosage of 5 mg/kg body weight, it was able to alter the impaired drug detoxifying system which was observed in the Sarcoma-180 bearing mice."	( Modulation of the impaired drug metabolism in sarcoma-180-bearing mice by echitamine chloride. Govindasamy, S; Mathuram, V; Saraswathi, V; Subramanian, S, 1999)	0.53

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (20.00)	18.7374
1990's	4 (40.00)	18.2507
2000's	2 (20.00)	29.6817
2010's	1 (10.00)	24.3611
2020's	1 (10.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	50.36 (24.57)
Research Supply Index	2.48 (2.92)
Research Growth Index	4.77 (4.65)
Search Engine Demand Index	76.15 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (50.36)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (9.09%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (90.91%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
1-anilino-8-naphthalenesulfonate 1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.	2.31	1	aminonaphthalene; naphthalenesulfonic acid	fluorescent probe
3-methylcholanthrene Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.. 3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.	1.97	1	ortho- and peri-fused polycyclic arene	aryl hydrocarbon receptor agonist; carcinogenic agent
plumbagin plumbagin: a superoxide anion generator. plumbagin : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively.	6.96	1	hydroxy-1,4-naphthoquinone; phenols	anticoagulant; antineoplastic agent; immunological adjuvant; metabolite
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	1.96	1
minfiensine minfiensine: structure in first source	2.05	1
vincorine vincorine: structure in first source	2.05	1

Condition	Relationship Strength	Studies
Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.	2.02	1
Experimental Neoplasms [description not available]	2.02	1
Weight Reduction [description not available]	2.02	1
Weight Gain Increase in BODY WEIGHT over existing weight.	2.02	1
Weight Loss Decrease in existing BODY WEIGHT.	2.02	1
Infections, Plasmodium [description not available]	2.9	1
Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.	2.9	1
Sarcoma 180 An experimental sarcoma of mice.	2	1
Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)	6.97	1

chemdatabank.com